These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9053465)

  • 1. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.
    McQuaker IG; Hunter AE; Pacey S; Haynes AP; Iqbal A; Russell NH
    J Clin Oncol; 1997 Feb; 15(2):451-7. PubMed ID: 9053465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
    Rifkin R; Spitzer G; Orloff G; Mandanas R; McGaughey D; Zhan F; Boehm KA; Asmar L; Beveridge R
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):186-91. PubMed ID: 20511163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial.
    Maher DW; Lieschke GJ; Green M; Bishop J; Stuart-Harris R; Wolf M; Sheridan WP; Kefford RF; Cebon J; Olver I; McKendrick J; Toner G; Bradstock K; Lieschke M; Cruickshank S; Tomita DK; Hoffman EW; Fox RM; Morstyn G
    Ann Intern Med; 1994 Oct; 121(7):492-501. PubMed ID: 7520676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
    Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
    Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices.
    Singh AD; Parmar S; Patel K; Shah S; Shore T; Gergis U; Mayer S; Phillips A; Hsu JM; Niesvizky R; Mark TM; Pearse R; Rossi A; van Besien K
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):288-293. PubMed ID: 29061534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation.
    Bishop MR; Tarantolo SR; Geller RB; Lynch JC; Bierman PJ; Pavletic ZS; Vose JM; Kruse S; Dix SP; Morris ME; Armitage JO; Kessinger A
    Blood; 2000 Jul; 96(1):80-5. PubMed ID: 10891434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
    Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
    Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation.
    Gerds A; Fox-Geiman M; Dawravoo K; Rodriguez T; Toor A; Smith S; Kiley K; Fletcher-Gonzalez D; Hicks C; Stiff P
    Biol Blood Marrow Transplant; 2010 May; 16(5):678-85. PubMed ID: 20045479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
    Kim IH; Park SK; Suh OK; Oh JM
    Curr Med Res Opin; 2003; 19(8):753-9. PubMed ID: 14687447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
    Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
    J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).
    Sebban C; Lefranc A; Perrier L; Moreau P; Espinouse D; Schmidt A; Kammoun L; Ghesquieres H; Ferlay C; Bay JO; Lissandre S; Pérol D; Michallet M; Quittet P
    Eur J Cancer; 2012 Mar; 48(5):713-20. PubMed ID: 22248711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegfilgrastim to accelerate neutrophil engraftment following peripheral blood stem cell transplant and reduce the duration of neutropenia, hospitalization, and use of intravenous antibiotics: a phase II study in multiple myeloma and lymphoma and comparison with filgrastim-treated matched controls.
    Wannesson L; Luthi F; Zucca E; Rosselet-Christ A; Baglioni M; Marelli L; Ghielmini M; Ketterer N
    Leuk Lymphoma; 2011 Mar; 52(3):436-43. PubMed ID: 21323524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation.
    Khot A; Dickinson M; Stokes K; Harrison S; Burbury K; Fleming S; Wall D; Gambell P; Prince HM; Seymour JF; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):42-7. PubMed ID: 23146384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue.
    Nolan L; Lorigan P; Chilton S; Newman J; Else R; Smith P; Linch D; Sweetenham JW; Johnson PW
    Br J Haematol; 2007 Jun; 137(5):436-42. PubMed ID: 17433027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.
    Greenberg P; Advani R; Keating A; Gulati SC; Nimer S; Champlin R; Karanes C; Gorin NC; Powles RL; Smith A; Lamborn K; Cuffie C
    Bone Marrow Transplant; 1996 Dec; 18(6):1057-64. PubMed ID: 8971373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation.
    Stinson TJ; Adams JR; Bishop MR; Kruse S; Tarantolo S; Bennet CL
    Bone Marrow Transplant; 2000 Sep; 26(6):663-6. PubMed ID: 11041569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.